查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球中風管理市場：按類型、按應用：機會分析和產業預測（2022-2032）
市場調查報告書
商品編碼
1414711

全球中風管理市場：按類型、按應用：機會分析和產業預測（2022-2032）

Stroke Management Market By Type (Diagnostics, Therapeutics, Software), By Application (Ischemic Stroke, Haemorrhagic Stroke): Global Opportunity Analysis and Industry Forecast, 2022-2032
出版日期: | 出版商: Allied Market Research | 英文 230 Pages | 商品交期: 2-3個工作天內

價格

預計2022年全球卒中管理市場規模將達361億美元，2022年至2032年複合年成長率為7.4%，2032年將達740億美元。

中風管理市場-IMG1

中風是一種由於血管破裂或腦部血液阻塞而導致腦部血液供應突然中斷時發生的疾病。結果，腦組織缺氧，腦細胞迅速死亡。中風主要分為三種：缺血性中風、短暫性腦缺血發作、出血性中風。中風診斷和治療的綜合方法稱為中風管理。中風診斷包括磁振造影、頸超音波、腦血管血管造影術和血液檢查。中風可用組織纖溶酶原活化劑、抗凝血劑、抗血小板藥物和抗高血壓藥物治療。

中風發病率上升、診斷影像技術開拓以及遠端醫療在中風管理中的快速採用推動了中風管理市場的成長。

久坐的生活方式、不健康的飲食和高壓力等因素會導致中風率增加。例如，根據世界衛生組織 (WHO) 在 2022 年世界中風日發布的資料，中風是全球第二大死因。根據同一數據，一生中中風的風險增加了 50%，目前估計四分之一的人一生中會中風。中風發病率的增加增加了對有效治療和管理策略的需求，推動了中風管理市場的成長。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 中風發生率增加
      • 中風管理的技術開發
      • 對中風的認知顯著提高
    • 抑制因素
      • 中風診斷和治療費用高
    • 機會
      • 人工智慧和機器學習徹底改變中風管理

第4章中風管理市場：依類型

  • 概述
  • 診斷
  • 治療藥物
  • 軟體

第5章中風管理市場：依應用分類

  • 概述
  • 缺血性中風
  • 出血性中風

第6章中風管理市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第7章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2022年）

第8章 公司簡介

  • Abbott Laboratories
  • B. Braun SE
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cardinal Health
  • General Electric Company
  • Medtronic
  • Siemens AG
  • JLK
  • Heuron Co., Ltd.
  • Deepnoid Co., Ltd.
  • NeuraSignal, Inc.
  • Aidoc
  • Brainomix
  • METHINKS
  • Viz.ai, Inc.
  • iSchemaView, Inc.
  • Qure.ai
  • VasSol Inc.
  • Koninklijke Philips NV
  • Merck & Co. Inc
Product Code: A00539

According to a new report published by Allied Market Research, titled, "Stroke Management Market," The stroke management market was valued at $36.1 billion in 2022, and is estimated to reach $74 billion by 2032, growing at a CAGR of 7.4% from 2022 to 2032.

Stroke Management Market - IMG1

A stroke is a medical condition that occurs when the blood supply to the brain is abruptly cut off due to rupturing of blood vessels or blockage in blood supply to brain. This leads to depletion of oxygen to brain tissues, which results in the rapid death of brain cells. There are mainly three types of strokes namely ischemic stroke, transient ischemic attack, and hemorrhagic stroke. A comprehensive approach to the diagnosis and treatment of people who suffered from stroke is called stroke management. The diagnosis of stroke includes magnetic resonance imaging, carotid ultrasound, cerebral angiography, blood tests, and others. Stoke can be treated with tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive medicines.

The stroke management market growth is driven by rising incidence of stroke, technological development in diagnostic imaging, and surge in adoption of telemedicine for stroke management. Factors such as

1) sedentary lifestyle, unhealthy diets, and high stress levels leads to rise in incidences of stroke. For instance, according to the data published by World Health Organization (WHO), on World Stroke Day 2022, reported that stroke is the second leading cause of death across the globe. As per the same source, the lifetime risk of developing a stroke has increased by 50% and currently 1 in 4 people is estimated to have a stroke in their lifetime. This rise in stroke incidences has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the stroke management market.

In addition, the technological advancement in the diagnostic techniques also drives the market growth. The advanced imaging technologies such as

1) magnetic resonance imaging and angiography systems have improved the diagnosis of stroke and enhanced patient care. For instance, Siemens Healthineers, a global medical technology company has received the Food and Drug Administration (FDA) approval for its ARTIS icono ceiling. ARTIS icono ceiling is an angiography system used for the advanced procedures in the interventional cardiology. Thus, technological advancement in the stroke imaging techniques further boost the market growth.

However, the high cost of stroke diagnosis and treatment limit the growth of stroke management market. The economic burden of stroke is the major factor hampering the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the growth of stroke management market.

On the other hand, surge in adoption of artificial intelligence for stroke management, increase in awareness about preventive healthcare, and rise in geriatric population in developing countries are expected to create lucrative opportunities for market growth during the forecast period.

The stroke management market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into diagnostics, therapeutics, and software. The diagnostic segment is further categorized into magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The therapeutics segment is further divided into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. As per application, the market is bifurcated into ischemic stroke and hemorrhagic stroke.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global stroke management market are Abbott Laboratories, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, General Electric Company, Medtronic, Siemens AG, Aidoc, Brainomix, VasSol Inc., Qure.ai, Viz.ai, Inc., METHINKS, B Braun SE, iSchemaView, Inc., NeuraSignal, Inc., Deepnoid Co., Ltd., Heuron Co., Ltd., JLK, Koninklijke Philips N.V., and Merck & Co. Inc. Key players operating in the market have adopted product approval, acquisition, partnership, and product launch as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stroke management market analysis from 2022 to 2032 to identify the prevailing stroke management market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the stroke management market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global stroke management market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Type

  • Diagnostics
    • Type
    • Magnetic Resonance Imaging
    • Carotid Ultrasound
    • Cerebral Angiography
    • Electrocardiography
    • Echocardiography
    • Others
  • Therapeutics
    • Type
    • Tissue Plasminogen Activator
    • Anticoagulant
    • Antiplatelet
    • Antihypertensive
  • Software

By Application

  • Ischemic Stroke
  • Haemorrhagic Stroke

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • General Electric Company
    • Medtronic
    • Aidoc
    • Brainomix
    • Qure.ai
    • METHINKS
    • iSchemaView, Inc.
    • Deepnoid Co., Ltd.
    • Heuron Co., Ltd.
    • B. Braun SE
    • Koninklijke Philips N.V.
    • Abbott Laboratories
    • Cardinal Health
    • Siemens AG
    • VasSol Inc.
    • Viz.ai, Inc.
    • NeuraSignal, Inc.
    • JLK
    • Merck & Co. Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in the incidences of stroke
      • 3.4.1.2. Technological development in stroke management
      • 3.4.1.3. Significant increase in stroke awareness
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of stroke diagnostics and treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Artificial intelligence and machine learning are revolutionizing stroke management

CHAPTER 4: STROKE MANAGEMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Diagnostics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Diagnostics Stroke Management Market by Type
  • 4.3. Therapeutics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Therapeutics Stroke Management Market by Type
  • 4.4. Software
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: STROKE MANAGEMENT MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Ischemic Stroke
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Haemorrhagic Stroke
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: STROKE MANAGEMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Type
      • 6.3.4.5.2. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Type
      • 6.3.4.6.2. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by Application
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Type
      • 6.5.4.3.2. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Type
      • 6.5.4.4.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. B. Braun SE
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Boston Scientific Corporation
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Bristol-Myers Squibb Company
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Cardinal Health
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
  • 8.6. General Electric Company
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Medtronic
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
  • 8.8. Siemens AG
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. JLK
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
  • 8.10. Heuron Co., Ltd.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Key strategic moves and developments
  • 8.11. Deepnoid Co., Ltd.
    • 8.11.1. Company overview
    • 8.11.2. Key executives
    • 8.11.3. Company snapshot
    • 8.11.4. Operating business segments
    • 8.11.5. Product portfolio
  • 8.12. NeuraSignal, Inc.
    • 8.12.1. Company overview
    • 8.12.2. Key executives
    • 8.12.3. Company snapshot
    • 8.12.4. Operating business segments
    • 8.12.5. Product portfolio
    • 8.12.6. Key strategic moves and developments
  • 8.13. Aidoc
    • 8.13.1. Company overview
    • 8.13.2. Key executives
    • 8.13.3. Company snapshot
    • 8.13.4. Operating business segments
    • 8.13.5. Product portfolio
  • 8.14. Brainomix
    • 8.14.1. Company overview
    • 8.14.2. Key executives
    • 8.14.3. Company snapshot
    • 8.14.4. Operating business segments
    • 8.14.5. Product portfolio
    • 8.14.6. Key strategic moves and developments
  • 8.15. METHINKS
    • 8.15.1. Company overview
    • 8.15.2. Key executives
    • 8.15.3. Company snapshot
    • 8.15.4. Operating business segments
    • 8.15.5. Product portfolio
    • 8.15.6. Key strategic moves and developments
  • 8.16. Viz.ai, Inc.
    • 8.16.1. Company overview
    • 8.16.2. Key executives
    • 8.16.3. Company snapshot
    • 8.16.4. Operating business segments
    • 8.16.5. Product portfolio
    • 8.16.6. Key strategic moves and developments
  • 8.17. iSchemaView, Inc.
    • 8.17.1. Company overview
    • 8.17.2. Key executives
    • 8.17.3. Company snapshot
    • 8.17.4. Operating business segments
    • 8.17.5. Product portfolio
    • 8.17.6. Key strategic moves and developments
  • 8.18. Qure.ai
    • 8.18.1. Company overview
    • 8.18.2. Key executives
    • 8.18.3. Company snapshot
    • 8.18.4. Operating business segments
    • 8.18.5. Product portfolio
    • 8.18.6. Key strategic moves and developments
  • 8.19. VasSol Inc.
    • 8.19.1. Company overview
    • 8.19.2. Key executives
    • 8.19.3. Company snapshot
    • 8.19.4. Operating business segments
    • 8.19.5. Product portfolio
  • 8.20. Koninklijke Philips N.V.
    • 8.20.1. Company overview
    • 8.20.2. Key executives
    • 8.20.3. Company snapshot
    • 8.20.4. Operating business segments
    • 8.20.5. Product portfolio
    • 8.20.6. Business performance
  • 8.21. Merck & Co. Inc
    • 8.21.1. Company overview
    • 8.21.2. Key executives
    • 8.21.3. Company snapshot
    • 8.21.4. Operating business segments
    • 8.21.5. Product portfolio
    • 8.21.6. Business performance
    • 8.21.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. STROKE MANAGEMENT MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 08. STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. STROKE MANAGEMENT MARKET FOR HAEMORRHAGIC STROKE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. STROKE MANAGEMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. U.S. STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. CANADA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. CANADA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. UK STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. UK STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. ITALY STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. ITALY STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. CHINA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. CHINA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. INDIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. INDIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. AUSTRALIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA STROKE MANAGEMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 65. B. BRAUN SE: KEY EXECUTIVES
  • TABLE 66. B. BRAUN SE: COMPANY SNAPSHOT
  • TABLE 67. B. BRAUN SE: PRODUCT SEGMENTS
  • TABLE 68. B. BRAUN SE: PRODUCT PORTFOLIO
  • TABLE 69. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 70. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 71. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 72. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 73. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 74. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 75. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 76. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 77. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 78. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 79. CARDINAL HEALTH: PRODUCT SEGMENTS
  • TABLE 80. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 81. GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
  • TABLE 82. GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
  • TABLE 83. GENERAL ELECTRIC COMPANY: PRODUCT SEGMENTS
  • TABLE 84. GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
  • TABLE 85. GENERAL ELECTRIC COMPANY: KEY STRATERGIES
  • TABLE 86. MEDTRONIC: KEY EXECUTIVES
  • TABLE 87. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 88. MEDTRONIC: PRODUCT SEGMENTS
  • TABLE 89. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 90. SIEMENS AG: KEY EXECUTIVES
  • TABLE 91. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 92. SIEMENS AG: PRODUCT SEGMENTS
  • TABLE 93. SIEMENS AG: PRODUCT PORTFOLIO
  • TABLE 94. SIEMENS AG: KEY STRATERGIES
  • TABLE 95. JLK: KEY EXECUTIVES
  • TABLE 96. JLK: COMPANY SNAPSHOT
  • TABLE 97. JLK: PRODUCT SEGMENTS
  • TABLE 98. JLK: PRODUCT PORTFOLIO
  • TABLE 99. HEURON CO., LTD.: KEY EXECUTIVES
  • TABLE 100. HEURON CO., LTD.: COMPANY SNAPSHOT
  • TABLE 101. HEURON CO., LTD.: PRODUCT SEGMENTS
  • TABLE 102. HEURON CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 103. HEURON CO., LTD.: KEY STRATERGIES
  • TABLE 104. DEEPNOID CO., LTD.: KEY EXECUTIVES
  • TABLE 105. DEEPNOID CO., LTD.: COMPANY SNAPSHOT
  • TABLE 106. DEEPNOID CO., LTD.: PRODUCT SEGMENTS
  • TABLE 107. DEEPNOID CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 108. NEURASIGNAL, INC.: KEY EXECUTIVES
  • TABLE 109. NEURASIGNAL, INC.: COMPANY SNAPSHOT
  • TABLE 110. NEURASIGNAL, INC.: PRODUCT SEGMENTS
  • TABLE 111. NEURASIGNAL, INC.: PRODUCT PORTFOLIO
  • TABLE 112. NEURASIGNAL, INC.: KEY STRATERGIES
  • TABLE 113. AIDOC: KEY EXECUTIVES
  • TABLE 114. AIDOC: COMPANY SNAPSHOT
  • TABLE 115. AIDOC: PRODUCT SEGMENTS
  • TABLE 116. AIDOC: PRODUCT PORTFOLIO
  • TABLE 117. BRAINOMIX: KEY EXECUTIVES
  • TABLE 118. BRAINOMIX: COMPANY SNAPSHOT
  • TABLE 119. BRAINOMIX: PRODUCT SEGMENTS
  • TABLE 120. BRAINOMIX: PRODUCT PORTFOLIO
  • TABLE 121. BRAINOMIX: KEY STRATERGIES
  • TABLE 122. METHINKS: KEY EXECUTIVES
  • TABLE 123. METHINKS: COMPANY SNAPSHOT
  • TABLE 124. METHINKS: PRODUCT SEGMENTS
  • TABLE 125. METHINKS: PRODUCT PORTFOLIO
  • TABLE 126. METHINKS: KEY STRATERGIES
  • TABLE 127. VIZ.AI, INC.: KEY EXECUTIVES
  • TABLE 128. VIZ.AI, INC.: COMPANY SNAPSHOT
  • TABLE 129. VIZ.AI, INC.: PRODUCT SEGMENTS
  • TABLE 130. VIZ.AI, INC.: PRODUCT PORTFOLIO
  • TABLE 131. VIZ.AI, INC.: KEY STRATERGIES
  • TABLE 132. ISCHEMAVIEW, INC.: KEY EXECUTIVES
  • TABLE 133. ISCHEMAVIEW, INC.: COMPANY SNAPSHOT
  • TABLE 134. ISCHEMAVIEW, INC.: PRODUCT SEGMENTS
  • TABLE 135. ISCHEMAVIEW, INC.: PRODUCT PORTFOLIO
  • TABLE 136. ISCHEMAVIEW, INC.: KEY STRATERGIES
  • TABLE 137. QURE.AI: KEY EXECUTIVES
  • TABLE 138. QURE.AI: COMPANY SNAPSHOT
  • TABLE 139. QURE.AI: PRODUCT SEGMENTS
  • TABLE 140. QURE.AI: PRODUCT PORTFOLIO
  • TABLE 141. QURE.AI: KEY STRATERGIES
  • TABLE 142. VASSOL INC.: KEY EXECUTIVES
  • TABLE 143. VASSOL INC.: COMPANY SNAPSHOT
  • TABLE 144. VASSOL INC.: PRODUCT SEGMENTS
  • TABLE 145. VASSOL INC.: PRODUCT PORTFOLIO
  • TABLE 146. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 147. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 148. KONINKLIJKE PHILIPS N.V.: SERVICE SEGMENTS
  • TABLE 149. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 150. MERCK & CO. INC: KEY EXECUTIVES
  • TABLE 151. MERCK & CO. INC: COMPANY SNAPSHOT
  • TABLE 152. MERCK & CO. INC: PRODUCT SEGMENTS
  • TABLE 153. MERCK & CO. INC: PRODUCT PORTFOLIO
  • TABLE 154. MERCK & CO. INC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. STROKE MANAGEMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF STROKE MANAGEMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN STROKE MANAGEMENT MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN STROKE MANAGEMENT MARKET (2022-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL STROKE MANAGEMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. STROKE MANAGEMENT MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. STROKE MANAGEMENT MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF STROKE MANAGEMENT MARKET FOR HAEMORRHAGIC STROKE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. STROKE MANAGEMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 19. U.S. STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. CANADA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. MEXICO STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. GERMANY STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. FRANCE STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. UK STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. ITALY STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. SPAIN STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. REST OF EUROPE STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CHINA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. INDIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. AUSTRALIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. SOUTH KOREA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. BRAZIL STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SAUDI ARABIA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH AFRICA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF LAMEA STROKE MANAGEMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 42. COMPETITIVE DASHBOARD
  • FIGURE 43. COMPETITIVE HEATMAP: STROKE MANAGEMENT MARKET
  • FIGURE 44. TOP PLAYER POSITIONING, 2022
  • FIGURE 45. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. B. BRAUN SE: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. B. BRAUN SE: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. CARDINAL HEALTH: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. CARDINAL HEALTH: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. GENERAL ELECTRIC COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. MEDTRONIC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. MEDTRONIC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. SIEMENS AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 67. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. KONINKLIJKE PHILIPS N.V.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 71. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. MERCK & CO. INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 74. MERCK & CO. INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 75. MERCK & CO. INC: REVENUE SHARE BY REGION, 2021 (%)